跳至主要内容
临床试验/NCT02102503
NCT02102503已完成不适用

Motivational Interviewing and Medication Review in the Secondary Prevention of Coronary Heart Disease

Göran Petersson1 个研究点 分布在 1 个国家目标入组 417 人开始时间: 2013年10月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
417
试验地点
1
主要终点
Percentage of patients who achieve the treatment goal for Low density lipoprotein cholesterol (LDL-C)

研究概览

简要总结

Low medication adherence in patients with coronary heart disease increases mortality.

This study investigates if an intervention of medication review and counselling can improve patients' medication adherence and treatment results.

详细描述

The study will investigate the effects of medication review and Motivational Interviewing (MI) on patients with Coronary Heart Disease (CHD). Clinical pharmacists competent in MI and cardiology will conduct medication interviews and medication reviews at the outpatient clinic. The intervention will continue during 9 months, with interviews and reviews as needed.

Follow-up of results will take place 16 months after inclusion (corresponding to 4 months after the end of intervention).

The MI-Component will be quality assured by MITI 4.2-coding (Motivational Interviewing Treatment Integrity). The study will investigate effects on clinical outcomes, medication adherence, patients´ beliefs about medicines and quality of life.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Admitted for angiography
  • •Verified Coronary Artery Disease (ICD-10 I20-I21)
  • •Planned for follow up at the out-patient clinic (standard treatment)
  • •Swedish speaking

排除标准

  • •Cognitive impairment or any othe condition making interview or phone calls impossible.
  • •Non-participation in the standard follow-up
  • •Prior participation in this study

研究组 & 干预措施

MI and Medication review

Experimental

The intervention starts three months post-discharge after the standard treatment at the out-patients clinic. A medication review focused on cardiovascular drugs, and a counselling session with a clinical pharmacist using Motivational Interviewing (MI)-approach, and a follow-up phone call two weeks later. For patients with negative beliefs about medicines, three additional MI-sessions in clinic or by phone are planned together with the patient. Irrespective of beliefs the intervention ends with a second medication review and counselling session, which is coordinated with the 12-months post-discharge follow-up in primary care.

干预措施: Standard Treatment (Behavioral)

MI and Medication review

Experimental

The intervention starts three months post-discharge after the standard treatment at the out-patients clinic. A medication review focused on cardiovascular drugs, and a counselling session with a clinical pharmacist using Motivational Interviewing (MI)-approach, and a follow-up phone call two weeks later. For patients with negative beliefs about medicines, three additional MI-sessions in clinic or by phone are planned together with the patient. Irrespective of beliefs the intervention ends with a second medication review and counselling session, which is coordinated with the 12-months post-discharge follow-up in primary care.

干预措施: MI and Medication review (Behavioral)

Standard treatment

Active Comparator

Standard treatment at the cardiology out-patient clinic. Follow-up by nurse after two weeks and by physician after two months.

干预措施: Standard Treatment (Behavioral)

结局指标

主要结局

Percentage of patients who achieve the treatment goal for Low density lipoprotein cholesterol (LDL-C)

时间窗: 16 months

According to Swedish guidelines the goal is \< 1,8mmol/L or at least 50% reduction from baseline.

次要结局

  • Percentage of patients adherent to cholesterol lowering treatment(16 months)
  • Percentage of patients adherent to preventive medication: Angiotensin Converter Enzyme inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB)(16 months)
  • Percentage of patients adherent to preventive medication: P2Y12-antagonist(16 months)
  • Percentage of patients with Systolic Blood Pressure <140(16 months)
  • Changes in Quality of Life(16 months)
  • Percentage of patients adherent to preventive medication: Acetylsalicylic acid (ASA)(16 months)
  • Percentage of patients adherent to preventive medication: Beta-blocker(16 months)
  • Number of Cardiovascular Re-admissions and Emergency Department visits(16 months)

研究者

申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Göran Petersson

Professor of Health Informatics with focus on Pharmaceutical Science

Linnaeus University

研究点 (1)

Loading locations...

相似试验